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THE IMPACT OF SOCIAL DETERMINANTS OF HEALTH ON PLACENTAL 
CPG METHYLATION AND SEVERITY OF NEURODEVELOPMENTAL 
BURDEN IN CHILDREN BORN EXTREMELY PRETERM 
SARA JACOBELLIS 
ABSTRACT 
Background: It has long been accepted that the environment we experience can impact 
our well-being; throughout recorded history, the greatest prevalence and severity of 
disease has been experienced by marginalized and underserved populations. However, 
the translation of such nontangible influences into biological changes in our health has 
been elusive until the recent advent of epigenetic studies. Modifications outside of the 
genome play a critical role in regulating transcription as well as subsequent gene 
expression without altering DNA sequencing by controlling the accessibility of the DNA 
for interaction with key initiation proteins and enzymes. These modifications, which 
include DNA methylation, histone acetylation, and small noncoding microRNA 
regulation, have increasingly been found to have a fluid, adaptive response to experiences 
throughout life. Based on the literature supporting societal stressors negatively impacting 
neurologic outcome, as well as elucidating an association between epigenetic changes 
and adverse neurologic outcome, we hypothesize that alterations in CpG methylation 
sites associated with socioeconomic adversity will also be correlated with the incidence 
of Neurodevelopmental Disorders. 
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Methods: 889 of the 1,506 neonates initially recruited from 14 medical centers 
throughout the United States at their time of birth qualified to participate in this study. 
Placental samples were taken immediately following delivery and neonatal blood samples 
were taken within the first month of life. Children that survived were followed at 2 years 
old and 10 years old to evaluate for the presence of four possible Neurodevelopmental 
Disorders: cognitive impairment, Cerebral Palsy, Autism Spectrum Disorder, and 
epilepsy. Taking this data as well as demographic information into consideration, the 
entire cohort included in this study was first evaluated for aberrant methylation levels at 
33 CpG sites previously associated with socioeconomic adversity to analyze the degree of 
significant correlation between altered methylation status and Neurodevelopmental 
Disorder prevalence. A secondary Epigenome-Wide Association Study was conducted 
for each of our 889 participants to pinpoint significant changes in CpG methylation in 
order to evaluate the relationship between altered methylation of particular genes and 
incidence of Neurodevelopmental Disorders. Taking the previous finding that cognitive 
impairment imposes a greater burden on both the individual and society than non-
cognitive impairment into consideration, both analyses were categorized based on this 
measure of impairment severity: No Impairment, Non-Cognitive Impairment (diagnosed 
with Cerebral Palsy, Autism Spectrum Disorder, and/or epilepsy without cognitive 
deficit), and Cognitive Impairment (cognitive deficit with or without other 
neurodevelopmental disorders present). 
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Results: Primary analysis of the 33 CpG sites previously associated with socioeconomic 
adversity did not reveal any significant associations with Non-Cognitive or Cognitive 
Impairment. However, cg15519318 and cg10613063 (located in the PCCB gene) were 
marginally associated with Non-Cognitive Impairment while cg02765535 (located in the 
NTN4 gene) was marginally associated with Cognitive Impairment. Secondary analysis 
of the entire epigenome found 4 CpG sites significantly associated with Non-Cognitive 
Impairment (cg07322235, cg13592565, cg13723879, and cg24387818) as well as 4 CpG 
sites significantly associated with Cognitive Impairment (cg23081580, cg14134658, 
cg00762003, and cg08546514). 
 
Discussion: We were not able to define a significant relationship between the CpG 
methylation sites related to socioeconomic adversity and adverse neurodevelopmental 
outcomes. This could stem from several causes, including insufficient power as well as 
limiting our evaluation of the extensive list of environmental influences to the four 
measures of societal stress focused on in this study (low educational attainment, single 
relationship status, public health insurance, and receiving supplemental nutrition 
assistance). Investigating the epigenome for differential methylation that was 
significantly associated with the incidence of Neurodevelopmental Disorders identified 
CpGs associated with several important genes, including genes coding for Neuregulin-3 
(NRG3) and Premature Ovarian Failure Actin Binding Protein 1B (POF1B) region with 
Non-Cognitive Impairment as well as genes coding for Six-Transmembrane Epithelial 
Antigen of Prostate 2 Metalloreductase (STEAP2), Ly1 Antibody Reactive (LYAR), 1-
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Acylglycerol-3-Phosphate O-Acyltransferase 3 (AGPAT3), and Ninein-like protein 
(NINL) with Cognitive Impairment.  
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Neurodevelopmental Disorders (NDDs) negatively impact the quality of life of a 
significant portion of the global population, with nearly 1 in 6 children diagnosed in the 
United States alone.1 This term is broadly used to describe conditions with atypical 
maturation and subsequent function of the central nervous system that can manifest in a 
myriad of phenotypic expressions.2,3 These conditions are characterized by delayed 
and/or disturbed skill development in domains such as motor, social, language, and 
cognition.4 Common diagnoses include Intellectual Disability, Autism Spectrum 
Disorder, Cerebral Palsy, and Epilepsy.5 Intellectual Disability (ID) is a common 
neurodevelopmental disorder of cognitive impairment that impacts approximately 1-3% 
of the global population. This diagnosis is characterized by limited intellectual function 
and adaptive behavior and is classified by having an Intelligence Quotient (IQ) < 70.6 
Autism Spectrum Disorder (ASD) is a group of disorders affecting approximately 2% of 
the population characterized by dysfunctional social ability, restrictive and repetitive 
behavior, and impaired communication skills.7 Cerebral Palsy (CP) encompasses a range 
of disordered movement and posture that afflicts 2-3 per 1000 live births.8 Epilepsy is a 
neurological disease involving recurrent, unprovoked seizures that impacts 1.2% of the 
US population.9 Given the vast collection of influences, both intrinsic and extrinsic to 
fetal development, that contribute to the etiology of these heterogenous disorders, NDDs 
have a spectrum of presentation and comorbidity that sheds light on the intricacies of 
neurodevelopment. 




Many diseases or disorders stem from heritable genetic mutations. For example, 
tuberous sclerosis complex (TSC) can arise from the autosomal inheritance of mutations 
in either TSC1, a gene located on chromosome 9 and encodes for the protein hamartin, or 
TSC2, a gene located on chromosome 16 and directs production of the protein tuberin. 
Both hamartin and tuberin play roles in the regulation of protein synthesis, and in the 
setting of tuberous sclerosis complex they cause hyperactivation of the mTOR signaling 
pathway. This upregulation of vital cell processes, such as cellular proliferation and 
metabolism, manifests as multisystem benign tumor growth, seizures, cognitive 
impairment, and ASD.10 Familial transmission of X-linked mutations has also been 
identified, such as variants of the Chloride Voltage-Gated Channel 4 (CLCN4) gene 
responsible for a chloride/hydrogen ion exchanger in the brain that regulates ion 
homeostasis and intracellular trafficking. These mutations have been found to cause 
global developmental delays, ID, behavior disorders, and epilepsy.11  
In addition to these heritable variants, numerous de novo mutations (DNMs) 
involved in crucial processes throughout fetal development have been associated with 
atypical neurodevelopment. Sporadic changes to Tubulin Alpha 1A (TUBA1A), which 
codes for the structural protein of the same name, Ras Homolog Family Member B 
(RHOB), which produces Rho-GTPase for regulation of cell signaling, and F-Box Only 
Protein 31 (FBXO31), which is associated with ubiquitination for proteasomal 
degradation, have been implicated in the development of spastic type Cerebral Palsy.12 
Some of the most common variants linked to epilepsy are within Sodium Voltage-Gated 
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Channel Alpha Subunit 1 (SCN1A), a gene that contributes to the neuronal voltage-gated 
sodium channel; these mutations give rise to a spectrum of epileptic syndromes, 
including generalized epilepsy with febrile seizures plus, myoclonic-atonic epilepsy, and 
Dravet Syndrome.13,14 Notable mutations involved in ASD include Sodium Voltage-
Gated Channel Alpha Subunit 2 (SCN2A), which codes for another component of the 
neuronal voltage-gated sodium channel that coordinates excitation, Chromodomain 
Helicase DNA Binding Protein 8 (CHD8), which is responsible for chromatin 
remodeling, and Pogo Transposable Element Derived with ZNF Domain (POGZ), which 
produces a vital mitotic protein.15,16 DNMs in Catenin Beta-1 (CTNNB1), whose product 
beta-catenin plays a vital role in Wnt signaling, as well as Protein Phosphatase, 
Mg2+/Mn2+ Dependent 1D (PPM1D), which produces a phosphatase that regulates p53-
mediated stress response, have been associated with intellectual disability.17,18 Many 
genetic mutations have been linked to multiple disorders, such as the various missense 
mutations and polyalanine tract expansions within Aristaless Related Homeobox (ARX). 
This gene codes for a homeobox protein that coordinates neuronal migration, that have 
been associated with epilepsy, intellectual disability, autism, dystonia, and ataxia.19 This 
varying phenotypic expression lends itself to the overlapping of symptoms experienced 
by NDD patients as well as frequent comorbidity. 
 
Environment 
 In addition to the adverse effects genetic variance can have on neurologic 
outcomes, growing interest has been focused on the substantial impact the environment 
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can have on one’s health. This study of external influences has its roots in investigating 
the tragic outcomes following exposure to chemicals such as aluminum, lead, and 
mercury. Exposure to these metals can occur through contaminated soil, water sources, 
and even household paint in the case of lead,20 leading to the onset and/or exacerbation of 
various neurological deficits, including intellectual disability, autism spectrum disorder, 
epilepsy, cerebral palsy, and behavioral problems.21–23 While all humans are susceptible 
to the toxic effects of these metals, the fetal period and the first three years of life have a 
markedly higher risk for adverse outcomes via perturbation of vital neurodevelopmental 
processes, such as cortical functional differentiation, synaptogenesis, and myelination.20 
Although initially assumed to be protected by the placental barrier, these chemicals are 
capable of passing directly to the fetus during gestation at varying rates.24–26 In fact, the 
placenta has been found to enhance the transfer of mercury, with concentrations in 
umbilical cord red blood cells being as high as 100% greater than that of maternal red 
blood cells, resulting in graver effects at smaller maternal doses than previously 
anticipated.27,28  
Another component of the environmental impact on health is exposure to harmful 
pathogens. Cyanobacteria, an alga that can bloom in fresh or brackish water, releases the 
toxic amino acid β-Methylamino-L-alanine (BMAA) that can cause cognitive impairment 
as well as future neurodegenerative disease upon exposure. Due to this toxins’ ability to 
cross the placenta, pass to the infant via lactation, and traverse the rudimentary blood-
brain barrier (BBB) with a notably higher rate of uptake than in adults, BMAA’s effects 
are experienced most severely by younger children still undergoing neurodevelopment.29 
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Other maternal viral and bacterial infections have been found to have detrimental effects 
on fetal neurodevelopment, including influenza increasing fetal risk for ASD and low 
verbal Intelligence Quotient (IQ) scores.30 Direct infection of the child can also result in 
detrimental outcomes, such as neonatal Herpes Simplex Virus (HSV) causing severe 
cognitive impairment and seizure disorder.31 
While it is clear that these negative maternal exposures increase the risk of fetal 
anomalies, elements that are normally considered protective factors for a mother’s health 
can also have detrimental effects on the fetus. Medications, in particular, that are 
prescribed to treat a vast array of maternal conditions can have teratogenic effects on the 
fetus. Valproate, an antiepileptic drug (AED) used in the treatment of seizures, bipolar 
disorder, and migraines, can cause neural tube defects, cognitive impairment with speech 
and psychomotor delay, ASD, and dyspraxia.32 Isotretinoin, a retinoid used to treat severe 
cystic acne, has severe and diffuse impacts on the fetus, including microcephaly33 with 
subsequent cerebral palsy, intellectual disability, ASD, and epielpsy.34 
 Additional complications can occur during pregnancy, birth, and early infancy 
that impose environmental strain on the developing child. Complications during the 
perinatal period such as hypoxic-ischemic events and stroke have a longstanding 
association with significant risk for causing and/or exacerbating NDDs, particularly 
CP.12,35 Common maternal conditions such as gestational diabetes,36 gestational 
hypertension,37 and preeclampsia38 have also been shown to increase the incidence of 
NDDs including ASD, cognitive impairment, and epilepsy. Intrauterine growth restriction 
has been associated with varying severity of ID, while excessive intrauterine growth, 
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typically associated with gestational diabetes, shows greater association with ID 
comorbid with ASD.39 Intrauterine and placental infections with bacterial species such as 
Ureaplasma urealyticum, alpha-hemolytic Streptococcus, Corynebacterium sp. 
Gardnerella vaginalis, and Staphylococcus sp. have also been found to cause various 
neurological impairments including cognitive and motor delays. These occurrences have 
been connected via the presence of neonatal systemic inflammation, which is a byproduct 
of bacterial infection and has been associated with neurodevelopmental impairment.40 
Given the advancement of neonatal care within the last several decades, the increasing 
rate of extremely preterm (EP) infant survival has expanded our knowledge of the various 
consequences of immaturity and deficient organ growth.41 The risk and severity of each 
of the outcomes described increases with prematurity; of particular relevance, children 
who are born extremely premature are at greater risk for cognitive impairment with 
significantly lower IQ,42 CP, ASD, and epilepsy, as well as additional comorbidities 
among these NDDs.43,44 
 
Social Factors 
 In addition to these well-established aspects of our tangible environment, recent 
studies have shifted focus toward the impact our social interactions have on 
neurodevelopment. It has long been understood that underserved and marginalized 
populations experience a diminished quality of life, and an archetypal measure used to 
explain this relationship has been race/ethnicity.45,46 The persistence of racism in the 
fabric of our society has cultivated diffuse disparity among minorities, giving rise to 
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social, economic, and health inequity.47 Race and ethnicity have classically been used as 
a generalized measure of socioeconomic status (SES) to explain differences in various 
health outcomes, however, recent studies have broken down this blanket term to analyze 
specific experiences of adversity and indicators of deprivation that stem from this 
discrimination. Examples include fewer opportunities for higher-level education, use of 
public insurance due to inability to afford private options, single-parent families, and 
food insecurity. The extensive list of these societal elements found to influence overall 
health has come to be collectively referred to as social determinants of health (SDOH).47 
Due to the importance of external stimulation in promoting maturation and the 
heightened susceptibility of the nervous system to environmental influence during early 
childhood, NDDs are experienced with greater frequency and severity in low and 
moderate-income countries where malnourishment, insufficient access to structured 
education, and inadequate healthcare fail to provide the environment needed to ensure 
optimal development.48 
 
Cerebral Palsy and SES  
A recent US study found an increased risk for CP among children born to mothers 
with lower educational attainment (EA) as well as non-Hispanic black ethnicity, both of 
which are individual-level measures of socioeconomic status (SES).49 One study chose to 
consider not only individual-level SES through maternal ethnicity and maternal age, but 
also a composite neighborhood deprivation index of EA, income, and employment to 
evaluate the cumulative effects of deprivation on adverse neurologic outcomes. Maternal 
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minority status, low maternal age, and high levels of neighborhood deprivation were 
associated with increased rates of children with CP who were non-ambulant, had 
moderate to severe cognitive impairment, and severe comorbidities.50 A similar project 
evaluated both levels of SES and additionally considered the possibility of low area-level 
SES negatively impacting neurologic outcome without the presence of personal 
deprivation. Despite having an individual measure of high maternal EA, children living in 
low SES neighborhoods had an increased risk for non-ambulatory status CP, highlighting 
the role both direct and indirect deprivation can play in mediating development.51 
 
Epilepsy and SES 
 A recent Swedish study chose to evaluate the impact of neighborhood-level 
deprivation with and without the presence of personal deprivation, detecting a significant 
increase in outpatient registrations (healthcare use) in epilepsy patients that had recently 
moved from moderate to high levels of deprivation.52 Within the scope of individual SES 
indicators, parental EA was associated with the highest risk of epilepsy, which was not 
affected by the level of neighborhood deprivation.52 In furthering the study of area-level 
deprivation, a German project defined a positive correlation between neighborhood 
deprivation and antiepileptic drug (AED) adherence, bringing attention to the medical 
and social inequities faced daily through difficulty obtaining and paying for medication.53 
These social inequities were explored in a Nigerian study that sought to determine causal 
factors behind noncompliance. The most common reason for missed appointments was 
financial constraints that limited transportation and was seen disproportionately among 
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rural families with lower EA and overall SES. Similarly, the most frequent cause of poor 
drug compliance was cost, having the greatest impact on patients from lower social class. 
Following this socioeconomic trend, a positive correlation was found for both maternal 
EA and income with compliance.54  
An American study chose to expand these measures of SES to assess the impact 
of food insecurity on epilepsy, finding those experiencing this particular hardship were at 
greater risk for more acute healthcare use, via hospitalizations and emergency department 
encounters, more frequent healthcare use, lower quality of life, and greater experience of 
adverse effects from AEDs. These effects were significantly greater within the non-
Hispanic black population as well as among participants with public insurance.55  
 
Cognitive Impairment and SES 
The use of individual and residence-based SES measures has also been used in the 
context of ascertaining ID risk. A French study found a positively stratified risk among 
unemployment, low EA, and immigration status, with the greatest risk for severe ID 
among children living in highly deprived neighborhoods as well as having a single parent 
family.56 These trends were replicated in a Taiwanese study, which used the degree of 
neighborhood urbanization as an area-level SES indicator and correlated increased 
urbanization with decreased incidence of ID.57 Additionally, an Australian study 
associated increased risk of mild-moderate ID with increasing neighborhood-level social 
disadvantage.58 
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With regards to cognitive impairment, SES has proven to have a strong 
association with future outcomes. A recent UK study evaluating verbal and non-verbal IQ 
periodically from the age of 2 to 16 years old found not only a positive correlation 
between SES (quantified via parental education and occupation) and IQ but also a 
marked amplification of this gap in cognitive ability with progression through 
adolescence.59 The development of IQ facilitated by higher SES, and conversely the 
decline of intelligence scores seen in children with low SES, highlights the accumulating 
effect such social components can have when experienced throughout childhood.60 This 
is corroborated by a US study that found children born into the lower class, determined 
by parental education and occupation, had significantly lower Full-Scale IQ scores at 3 
years old than children born into the middle and upper class.61 
 
ASD and SES 
 Autism Spectrum Disorder presents an interesting divide in trends between US 
and international studies. American studies reveal a positive correlation between 
elements of SES, such as EA, and ASD prevalence.62 These differences are seen between 
ethnicities as well; a recent temporal study of metropolitan Atlanta spanning 1991-2010 
showed the greatest total number of ASD diagnoses among the non-Hispanic white 
population.63 In contrast, several studies based in Sweden64 and France56 have uncovered 
an association similar to those previously described among other NDDs. Parental income 
and lower occupation class were both negatively correlated with ASD prevalence.64 
Additionally, neighborhood deprivation, unemployment, immigration status, and single-
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parent families were associated with increased risk of ASD, with severe ID comorbidities 
most likely to occur with the highest composite score of deprivation.56 Comparing these 
outcomes with the US findings highlights the pitfalls of the American healthcare system. 
Unlike the standardized access to diagnostics and treatment experienced with Swedish 
healthcare, the stratified opportunities available in the US can lead to case ascertainment 
bias, which is proposed as a likely contributor to the inverse stratification of ASD 
prevalence.56 Despite these flaws, the metropolitan Atlanta study also revealed a greater 
rate of increase in ASD prevalence was found among the Hispanic and non-Hispanic 
Black populations, indicating an improvement in diagnostic and treatment availability.63 
 
Epigenetics 
Despite the well-established association between societal influences and adverse 
health outcomes, the mechanism of this biological manifestation of intangible factors had 
been elusive to the scientific community until very recently. The discovery of genetic 
mutations in the Methyl-CpG Binding Protein 2 (MECP2) gene and its causal role in 
adverse neurologic outcomes at the turn of the 21st century has brought about a new wave 
of research pointing to epigenetics as the malleable bridge between these two 
phenomena.65 
X-linked DNMs of MECP2, a gene vital for transcriptional regulation via 
epigenetic modification, has been extensively studied as a causal factor in the 
development of intellectual disability, ASD, and Rett Syndrome, a progressive 
developmental disorder affecting females that involves loss of motor control and speech, 
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cognitive impairment, and seizures.66 Investigating the disorders that result from 
dysregulation of epigenetic mechanisms has highlighted the vital role epigenetic 
mechanisms play in modulating our phenotypic expression and the fluid nature of our 
selective application of the genome throughout life.  
Epigenetic modifications occur to promote or downregulate the production of a 
given protein without altering the genetic sequence; this silencing or amplification results 
in varied phenotypic expression.67 One major contributor to this process is the post-
replication methylation of cytosine residues located 5’ to guanosine residues, better 
known as CpG sites. CpG methylation is catalyzed by DNA methyltransferase and 
prevents the binding of key proteins involved in transcription, leaving this portion of 
DNA in a repressed state.68 The presence of these methylations attracts additional binding 
proteins, such as the aforementioned MECP2, which in turn recruit enzymes that 
deacetylate histones; these modifications tighten chromatin structure, which further 
prevents gene expression.65 
 
Methylation and SES 
A recent study of this cohort identified 33 CpG sites within 21 genes associated 
with summative SES score, marital status, food insecurity, EA, and health insurance 
status.69 These methylation patterns were mostly influenced by maternal single status, 
which affected the FRY Microtubule Binding Protein (FRY) gene responsible for mitotic 
structural integrity essential for cortex development and the Apoptosis Inducing Factor 
Mitochondria Associated 1 (AIFM1) gene that induces programmed cell death.69 The 
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downregulation of these genes results in congenital NDDs, muscle atrophy, 
neurodegeneration, motor neuron disease, and severe encephalopathy.69 Overall, these 
methylation patterns associated with SES enriched pathways involved in cellular 
development, growth and proliferation, muscular and hematological system development, 
and immune cell trafficking.69 An additional study evaluated the impact of SES on 
imprinted genes, another form of epigenetic regulation that selectively represses genes in 
a parent-of-origin-specific manner, allowing for only one allele to be expressed for each 
gene.70 A separate study identified 32 differentially methylated regions (DMRs) in 
response to SES, ethnicity, EA, and income in genes such as Insulin-like Growth Factor 2 
(IGF2), which encodes the vital promoter of fetal growth, and Neuronatin (NNAT), which 
produces a protein that coordinates energy homeostasis, as well as the genes Maternally 
Expressed 3 (MEG3) and H19 Imprinted Maternally Expressed Transcript (H19) which 
are responsible for non-coding RNAs.71 IGF2 expression has also been found to 
modulate via differential DNA methylation in response to maternal depression and 
anxiety.72 These responses to maternal stress, which can be caused by social stressors and 
adversity, can be interpreted as fetal reprogramming in preparation for the hardships 
experienced by their mother with the assumption that the child will also experience these 
hardships in their lifetime. This could be beneficial in theory, as seen in the 
hypomethylation of Hydroxysteroid 11-β Dehydrogenase 2 (HSD11B2), who’s gene 
product is responsible for inactivating maternal cortisol, in children born into deprivation 
that results in lower cortisol levels and effective stress management in the child.73 
However, this modification can also be maladaptive, as proven by the hypermethylation 
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of the glucocorticoid receptor gene Nuclear Receptor Subfamily 3 Group C Member 1 
(NR3C1) in response to maternal material deprivation, resulting in low birth weight and 
increased risk for development of future disease in the child.74 
 
Methylation and NDDs 
 Considerable research has also been conducted to determine the extent to which 
epigenetic changes can predict long-term neurologic outcomes. A recent study identified 
10 genes involved in the Hypothalamic-Pituitary-Adrenal (HPA) axis, a key component 
of both neurodevelopment as well as placental physiology, to be significantly associated 
with cognitive ability at 10 years old. In particular, NR3C1 and Brain-Derived 
Neurotrophic Factor (BDNF), which promotes differentiation and plasticity, had the 
strongest association with moderate to severe cognitive impairment at age 10.75 A 
deficiency of maternal leptin, the hormone responsible for satiety and heightened activity, 
has been found to increase methylation of the Leptin (LEP) gene in the fetus with 
subsequent decreased locomotion and hypotonicity.70 Within a monozygotic twin study 
discordant for CP, differential methylation was noted in 25 genes. Most notably, 
Lymphotoxin-α (LTA), Lck Interacting Transmembrane Adaptor 1 (LIME1), immune 
signaling pathways genes (Heterogenous Nuclear Ribonucleoprotein L [HNRNPL], Ras 
Association Domain Family Member 5 [RASSF5], CD3-delta Molecule [CD3D], and 
Kalirin RhoGEF Kinase [KALRN]), and promoters of epileptic encephalopathy-
associated genes (TBC1 Domain Family Member 24 [TBC1D24], F-Box Only Protein 9 
[FBXO9], and Vasoactive Intestinal Peptide Receptor 2 [VIPR2]).76 The highest-ranked 
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DMRs occurred within the LTA gene, which encodes for the brain inflammatory regulator 
TNF-β, and LIME1, which regulates MAPK signaling, while other prevalent DMRs 
enriched cytokine secretion and regulation of leukocyte-mediated immunity. This 
significant alteration of expression among key neuroinflammatory factors and signaling 
pathways highlights their role in adverse fetal neurodevelopment.76 With regards to 
epilepsy, altered methylation levels in the promoter regions of genes associated with 
neuronal hyperactivity, including BDNF and the glutamate receptor subunits Glutamate 
Ionotropic Receptor AMPA Type Subunit 2 (GRIA2) and Glutamate Ionotropic Receptor 
NMDA Type Subunit 2B (GRIN2B), has been associated with its pathogenesis.77 
Additionally, aberrant methylation of the promoter region of the Reelin gene (RELN), 
which encodes for the neuronal migration protein Reelin, has been implicated in the 
development of hippocampal granule cell dispersion in Temporal Lobe Epilepsy.77 
Altered methylation of RELN has also been associated with the development of ASD, as 
well as the altered methylation of the Oxytocin Receptor (OXTR) gene and SH3 And 
Multiple Ankyrin Repeat Domains 3 (SHANK3), a gene coding for scaffolding protein 
that connects neurotransmitter receptors and ion channels to the cytoskeleton.78  




Given the extensive findings supporting the positive correlation between 
socioeconomic adversity and adverse neurologic outcome, as well as the recent studies 
that associated increased CpG methylation with both SES and NDD, our research was 
conducted to determine if methylation patterns associated with SES could accurately 
predict neurologic outcome. We hypothesized that epigenetic changes contribute to an 
increased risk of poorer neurological outcomes, and we tested this hypothesis by 
evaluating whether placental tissue methylation alterations of 33 CpG sites previously 
associated with socioeconomic adversity69 were also associated with poorer neurologic 
outcomes. In light of the significant impact social stressors can have on inducing preterm 
birth and, in turn, increased risk for NDDs,42–44,69,71 this study was conducted within the 
Extremely Low Gestational Age Newborn (ELGAN) cohort. This participant pool is 
comprised of children born at less than 28 weeks’ gestation that have been followed 
prospectively since birth. 
The primary aim of this study was to determine if the aberrant methylation at 33 
CpG sites associated with socioeconomic adversity (categorized as cumulative SES 
score, maternal education, marital status, and food insecurity) was also associated with 
adverse neurological outcomes at 10 years old (categorized as Non-Cognitive Impairment 
[CP, ASD, and epilepsy] and Cognitive Impairment [LPA]). 
The secondary aim of this study was to evaluate the relationship between 
neurodevelopmental impairment and altered methylation status at all CpG sites 
throughout the epigenome. This approach was also categorized by type of impairment.  





This study was conducted using participant data from the Extremely Low 
Gestational Age Newborn (ELGAN) cohort. This is a multicenter study that enrolled 
newborns during 2002-2004 born at 23-28 weeks’ gestation in data collection sites 
spanning 14 hospitals within 5 states.44 Informed consent was given by mothers either 
upon arrival at the hospital for delivery or shortly after giving birth. The Institutional 
Review Board of each participating site approved of this study. Of the 1,506 infants born 
to 1,249 mothers that originally consented to participate in this longitudinal panel study, 
1,198 children survived to ten years old.43 Children from whom blood spots were 
collected during the first postnatal month to assess levels of inflammatory biomarkers 
(n=966) were invited to take part in the 10-year follow-up, and from that group 889 
children agreed to participate. 
  
Placental Tissue Collection 
As previously described in prior research utilizing this database,75,79 a total of 
1,365 placentas were transported via a sterile exam basin following delivery to a separate 
room where sampling took place. Beneath the intact amnion at the midpoint of the 
longest distance between cord insertion and the placental disk was chosen as the location 
to remove a portion of the chorion and underlying trophoblast for each tissue sample. If 
this designated area of the amnion was not intact and chorionic tissue was already 
exposed, another area of the placental disk with preserved amnion was utilized. Sterile 
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forceps and scissors were used to gently pull back and cut the amnion in order to expose 
the chorion, and a piece of the underlying tissue was extracted with a second set of sterile 
forceps and scissors. Following removal, the tissue was placed in a sterile 2 mL 
cryogenic vial, treated with liquid nitrogen, and frozen at -80℃. Following collection at 
the 14 separate sites, frozen samples were sent to a microbiology laboratory in Boston, 
MA for processing and analysis.  
  
DNA Extraction and Epigenome-Wide Association Study (EWAS) 
A previous study69 outlined the removal, preparation, and analysis of a fraction of 
the placental tissue biopsy. Following a rinse with 1x phosphate-buffered saline to 
remove any residual blood, a 0.2g portion of the frozen sample was homogenized in the 
lysis Buffer RLT with β-mercaptoethanol, and both DNA and RNA strands longer than 
18 nucleotides were extracted by an AllPrep DNA/RNA/miRNA Universal Kit (Qiagen, 
Valencia CA). Unmethylated cytosines in the extracted DNA fragments were then 
bisulfite-converted to uracil by the EZ DNA kit (Zymo Research, Irvine, CA) and 
subsequently read as thymine residues, leaving the remaining cytosines to be quantified 
by the Infinium MethylationEPIC BeadChip (Illumina, San Diego, CA). This chip 
contains probes that measure the methylation level of over 850,000 CpG sites at single 
nucleotide resolution.80 Samples were randomized among plates and chips to minimize 
the batch effect. In accordance with previous recommendations,81 this data was then 
imported into R for preprocessing using the minfi package.82 Following quality control 
for failed samples and duplicates, 426 samples were retained for analysis. A normal-
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exponential out-of-band correction method was implemented for background subtraction 
and dye normalization, followed by functional normalization that used the first two 
principal components of the control matrix.83 After additional quality control excluded 
806 probes with a p-value > 0.01 for 5% or more of our samples, 856,832 CpG sites were 
utilized for assessment. Calculated methylation levels were expressed as β values (β= 
methylated allele intensity (M)/[unmethylated allele intensity (U) + methylated allele 
intensity (M) + 100]) and were logit transformed to M values for statistical analyses.84 
  
Measures of Socioeconomic Adversity 
This study chose to replicate the SES variables previously utilized to associate 33 
CpG sites with socioeconomic adversity: maternal educational attainment, marital status, 
type of health insurance, and food insecurity (Table 1).69 SES adversity indicators for 
these measures include attaining a high school diploma or less, single relationship status, 
public health insurance, and receiving supplemental nutrition assistance (food stamps), 
respectively. This information was collected through a structured interview of the mother 
at enrollment for the ELGAN study and at 10-year data collection. 
As many of these hardships are not experienced in isolation, a summative risk 
score of each SES indicator was created to evaluate the cumulative effect of experiencing 
multiple forms of socioeconomic adversity simultaneously. This is a sum of the 
previously mentioned hardships reported by each family with scores ranging from 0-4. 
The summative risk score was dichotomized as less than or equal to 1 (0 and 1) and 
greater than or equal to 2 (2, 3, 4), with scores of 2+ SES categories indicating greater 
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prenatal socioeconomic adversity based on previous studies of SES and placental CpG 
methylation that highlight the significance of cumulative effects.73,85 
 
Measures of Neurodevelopment 
 All measures of neurodevelopment were previously outlined in a study of the 
comorbidity and severity of neurodevelopmental burden within the ELGAN cohort.43 
 
Latent Profile Analysis Using Intellectual Quotient and Executive Function 
Given its stronger predictive ability of academic achievement44 as well as 
individual and societal long-term burden86 when compared to IQ alone, Latent Profile 
Analysis (LPA) was used to classify participants into “Cognitive Functional Classes” 
based on their Intelligence Quotient and Executive Function. 
Intelligence Quotient (IQ) was measured via the School-Age Differential Ability 
Scales II (DAS-II)87 Verbal and Nonverbal Reasoning Scales.88 Due to the strong 
correlation of DAS-II Verbal and Nonverbal IQ scores within this sample, overall IQ was 
determined as the mean of their scores. An overall IQ score of less than 70, or more than 
2 standard deviations below the normative mean (100), was classified as intellectually 
disabled. All cognitive exams were administered by certified child psychologists. 
Executive Function (EF) and attention were assessed using the DAS-II along with the 
Developmental Neuropsychological Assessment-II (NEPSY-II)89 to measure auditory 
attention, set switching and inhibition, verbal working memory, concept generation, and 
mental flexibility. 
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LPA subgrouping corresponded with levels of Cognitive Functional Class (CFC): 
CFC 1 (normal) with mean IQ and EF scores within normal range on all measures, CFC 2 
(low-normal) with mean IQ and EF scores 0.5-1 standard deviation (SD) below the norm, 
CFC 3 (moderate impairment) with mean IQ and EF scores 1.5-2.5 SD below the norm, 
and CFC 4 (severe impairment) with mean IQ and EF scores 3-4 SD below the norm. 
Participants were identified as having cognitive impairment if they fell under the 
classification of CFC 3 or CFC 4.43  
 
Cerebral Palsy 
Neurological examiners assessed participants for CP by utilizing a standardized-
manual and data collection form, along with viewing an instructional CD to minimize 
examiner variability.90 
  
Autism Spectrum Disorder 
After participants completed the Social Communication Questionnaire,91 the 
parents of children deemed to be at risk for ASD were asked to take part in the Autism 
Diagnostic Interview-Revised (ADI-R).92 Those whose ADI-R score met the criteria for 
ASD were subsequently given the Autism Diagnostic Observation Schedule-2 (ADOS-
2).93 Official classification with ASD in this study required participants to meet the 
standardized criteria outlined in both ADI-R and ADOS-2. All evaluators were given 
research-level training in the administration and scoring of these assessments. 
  




Study coordinators aided the parents of participants in completing part one of a 
validated seizure screen for their child.94 The parents of children with a positive part one 
screen completed a structured interview with a pediatric epilepsy specialist who rated the 
events as seizure or not-seizure. Interview responses were reviewed and rated by a second 
epilepsy specialist to classify the described events as seizures or not-seizures. A third 
epilepsy specialist was introduced for the 3% of participants for which the first two 
epilepsy specialists were in disagreement. Epileptologists were unable to interview 43 of 
the 273 participants with a positive initial screening, however inverse probability 
weighting95 based on gestational age and initial seizure screen result was used to account 
for this missing data. For the purposes of this study, a diagnosis of epilepsy required two 
or more unprovoked seizures.96 
 
Quantifying/Categorizing Severity of Impairment 
Children with non-cognitive neurodevelopmental disorders have been found to 
have less impact on their family as well as a higher likelihood of living independent lives 
in comparison to children with neurodevelopmental disorders that include cognitive 
impairment.43 Meanwhile, school failure secondary to cognitive impairment is the most 
costly childhood condition, both individually and societally, outside of complex chronic 
disease.86 Given these distinctions, a three-level categorization was devised to group 
participants based on their overall level of impairment severity. Children were placed in 
the No Impairment group (Category I) if they were free of any significant 
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neurodevelopmental impairment. The Non-Cognitive Impairment group (Category II) 
consisted of participants who were without cognitive deficit (IQ > 70, CFC 1 or 2) but 
were diagnosed with at least one of the other NDDs within this study (CP, ASD, and/or 
epilepsy). Finally, the Cognitive Impairment group (Category III) included all children 
with cognitive impairment regardless of the presence of comorbid NDDs (CP, ASD, 




The primary analysis evaluated the relationship between socioeconomic adversity 
and neurologic outcome through robust logistic regression models. These tests were 
implemented to determine whether aberrant methylation levels at 33 CpG sites associated 
with SES (Table 1) are correlated with prevalence and severity of neurodevelopmental 
impairment. These CpG sites were selected based on a previous study69 that determined 
their strong association with experiencing various forms of socioeconomic adversity by 
conducting an Epigenome-Wide Association Study. Methylation level served as the 
independent variable for each regression model while the dependent variable was the 
presence or absence of adverse neurodevelopment, which was categorized based on type 
of neurological burden. Participants were divided into groups of No Impairment 
(Category I), Non-Cognitive Impairment (Category II), and Cognitive Impairment 
(Category III), which correlated with their severity of their impairment. Participants 
included in the NCI category were diagnosed with ASD, CP, and/or epilepsy but had 
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normal cognitive ability (CFC 1 or CFC 2). The CI category consisted of all participants 
classified as CFC 3 or CFC 4 via LPA, regardless of comorbidity with other NDDs. Each 
regression model was adjusted for socioeconomic and clinical covariates, which were 
selected based on established associations with both methylation and NDDs including 
infant sex, gestational age, maternal age, and race. The range of β values was transformed 
from 0-1 to 0-100 to better visualize the changes in percent methylation reflected in the 
Odds Ratio (OR) outcomes. The criterion for a CpG site to be significantly associated 
with neurodevelopmental impairment was a p-value < 0.05. OR, logit OR estimate, SD, 
z-score, and p-value are reported for each regression.  
A secondary analysis investigated the possible correlation of altered CpG 
methylation with adverse neurologic outcomes by conducting an epigenome-wide 
analysis of methylation at the level of individual CpG sites. Similar to the first portion of 
this study, participants were categorized into No Impairment (NI), Non-Cognitive 
Impairment (NCI), and Cognitive Impairment (CI) and the models were adjusted for 
infant sex, gestational age, maternal age, and race. Given the increased probability for 
false positives created by conducting multiple comparisons, a False Discovery Rate 
(FDR) < 0.10 was used in order to maintain a low false-positive rate while limiting 
missed significant findings. The log-fold change of average M value (log2FC), average 
rate of gene expression (AveExpr), t-statistic, unadjusted and adjusted p-value, log-odds 
of differential methylation (B), standard error, and associated gene name are reported for 
each CpG site.  
   
 
25
Table 1: Epigenome-wide analysis of the association between DNA methylation and 
socioeconomic factors.69 
 
KEY: TSS1500=0–1500 bases upstream of Transcriptional Start Site; 
Body=between ATG and stop codon; 5’UTR= Untranslated Region 










cg09625398 8 - - -
cg26546864 15 C15orf26 TSS1500 North Shore
cg03873518 22 GRAMD4 Body North Shore
cg11230111 20 CDH4 Body -
cg12217222 1 DR1 5’UTR Island
cg15154763 18 C18orf63 TSS1500 North Shore
cg24032568 10 PPP2R2D Body -
cg09236163 15 C15orf26 1stExon Island
cg11173636 10 - - -
cg08707025 8 DLGAP2 Body Island
cg21574864 15 FAM103A1 Body South Shelf
cg10830144 11 - - -
cg15519318 12 - - -
cg01134296 17 MMP28 TSS1500 South Shore
Marital Status
cg21075783 19 - - -
cg14194715 13 FRY Body -
cg15555622 19 ZNF833P 5’UTR South Shelf
cg07980716 X AIFM1 Body -
cg10613063 3 PCCB Body -
cg22167148 1 - - North Shelf
cg00606069 X PHEX 3’UTR -
cg24715563 1 RHOU 3’UTR -
cg15090198 1 USP48 3’UTR -
cg00323466 4 KCNIP4 Body -
cg27037498 7 COA1 Body -
cg10904858 10 PLCE1 5’UTR South Shelf
cg05963700 8 - - -
cg02765535 12 NTN4 Body -
cg05186250 15 ZNF609 Body -
Food Stamps
cg00121303 20 MACROD2 ExonBnd -
cg01314054 6 - - -
Education
cg01412404 3 - - -
Insurance Status
cg19839372 6 - - -





Demographic characteristics, including infant sex, gestational age, birthweight, 
maternal age, and race, among the 889 participants that survived to age 10 were recorded 
and separated into the three previously designated categories of neurodevelopmental 
outcome (Table 2). The majority of this cohort had overall normal neurodevelopment (NI 
N=601, 67.6%), however approximately 1 in 4 children experienced moderate to severe 
cognitive impairment (CI N=214, 24.1%) and nearly 1 in 10 children were diagnosed 
with non-cognitive neurological disorders, including epilepsy, autism spectrum disorder, 
and cerebral palsy, without cognitive impairment (NCI N=74, 8.32%). Infant sex was 
uniformly stratified among the No Impairment and Non-Cognitive Impairment categories 
(NI female=310 [51.6%] vs male=291 [48.4%]; NCI female=37 [50.0%] vs male=37 
[50.0%]), however there was a slightly higher prevalence of cognitive impairment seen in 
males (CI: female=87 [40.7%] vs male=127 [59.3%]). While the percentage of 
participants with a gestational age of 25-26 weeks was comparable across all groups 
(NI=45.1%, NCI=41.9%, CI=45.8%), the proportion of participants born at 23-24 weeks 
gestation notably increases within the Cognitive Impairment category (CI=31.8%) and 
even more so within the Non-Cognitive Impairment category (NCI=39.2%). A similar 
trend is seen regarding birthweight: the percentage of participants with a birthweight z-
score >1 remains fairly constant for all types of impairment (NI=11.8%, NCI=10.8%, 
CI=11.2%), while the proportion of infants with a birthweight more than 2 SD below the 
mean (NI=4.66%) increases in those diagnosed with both cognitive (CI=8.41%) and non-
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cognitive (NCI=9.46%) impairments. Interestingly, there was a larger presence of 
children with a birthweight z-score <-1 in the cognitively impaired grouping (CI=16.8%) 
in comparison to those without impairment (NI=12.6%), yet a somewhat smaller 
population among those with NDDs but normal cognition (NCI=10.8%). Mean maternal 
age was comparable across the NI (29.7, SD=6.56) and NCI (29.4, SD= 6.70) groups but 
was lower for CI (27.97 SD=6.83). In evaluating participant race, the stratification of 
White, Black, and “Other” subjects was relatively similar among participants with solely 
non-cognitive impairment (NCI: W=75.7%, B=17.6%, O=6.76%) and those without 
impairment (NI: W=68.2%, B=20.9%, O=10.9%). In contrast to these categories, 
cognitive impairment was more notably prevalent among Black and “Other” children 
(W=44.1%, B=42.7%, O=13.3%).  
With regards to factors of socioeconomic adversity, among the 889 participants 
21.7% had a single parent, 14.6% had a parent with a high school diploma or less, 35.1% 
qualified for public insurance, and 22.6% qualified for supplemental nutrition assistance 
via food stamps.69 
 
Neurodevelopmental Impairment 
Among the 889 families that agreed to participate in the 10-year follow-up, five 
children were present but unable to complete the assessments and eleven did not 
accompany their caregiver to the update visit, resulting in 873 children that fulfilled the 
measures of neurodevelopment at age 10.44 Forty of these children were assigned the 
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lowest score on some if not all tests due to severe motor, visual, and cognitive 
disability.43 
Assessment of the cognitive ability of 873 children (100% of the recruited cohort 
at age 10 years) via Latent Profile Analysis found 214 participants to have moderate to 
severe cognitive impairment (CFC 3 or 4, respectively), equating to almost 1 in 4 subjects 
receiving this diagnosis. Of the 849 participants assessed for CP (97% of the cohort), 93 
children, or approximately 1 in 10 subjects, met the diagnostic criteria assessed for this 
study. Within the 857 participants assessed for ASD (98% of the cohort), 61, or nearly 1 
in 15 subjects, possessed clinically diagnosable features. Among the 845 participants 
evaluated for epilepsy (97% of the cohort), 66 participants, which is nearly 1 in 14 
children within the cohort, screened positive for this disorder.43 Based on these findings, 
the CI category included 214 participants, while the NCI category included 74 
participants (Table 2). 
When considering the entire cohort, 601 (67.6.%) children were without 
impairment, while 288 (32.4%) were found to have at least one neurodevelopmental 
disorder. Within the pool of participants diagnosed with neurodevelopmental impairment, 
the majority had a single diagnosis (N=171, 59.4%) in comparison to those with 
comorbid NDDs (two diagnoses N=90, 31.3%; three diagnoses N=25, 8.68%; four 
diagnoses N=2, 0.69%).43 Epilepsy had the highest rate of comorbidity, with 71% of 
participants having other NDDs (N=47): 41 subjects were comorbid with LPA 3 or 4, 
while 6 subjects were comorbid with ASD or CP (Table 2). Among the children that 
possessed more than one neurodevelopmental diagnosis, moderate to severe cognitive 
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impairment (CFC 3 or 4) ran the highest risk for comorbid NDDs. Participants with 
cognitive impairment were 5.3 times more at risk for epilepsy, 5.5 times more at risk for 
CP, and 7.1 times more at risk for ASD in comparison to those with normal cognition.43 
 
Table 2: Demographics and NDD Distribution of ELGAN Cohort at Age 10 Years 
 
No Impairment Non-Cognitive Impairment Cognitive Impairment
N=601 (67.6%)   N=74 (8.32%)   N=214 (24.1%)  
Sex:
Female 310 (51.6%) 37 (50.0%) 87 (40.7%) 
Male 291 (48.4%) 37 (50.0%) 127 (59.3%)
Gestational Age:
23-24 90 (15.0%) 29 (39.2%) 68 (31.8%) 
25-26 271 (45.1%) 31 (41.9%) 98 (45.8%) 
27 240 (39.9%) 14 (18.9%) 48 (22.4%) 
Birthweight Z-Score:
< -2 28 (4.66%) 7 (9.46%) 18 (8.41%) 
< -1 76 (12.6%) 8 (10.8%) 36 (16.8%) 
<= 1 426 (70.9%) 51 (68.9%) 136 (63.6%)
> 1 71 (11.8%) 8 (10.8%) 24 (11.2%)
Maternal Age (SD): 29.7 (6.56) 29.4 (6.70) 27.7 (6.83)
Race:
White 405 (68.2%) 56 (75.7%) 93 (44.1%) 
Black 124 (20.9%) 13 (17.6%) 90 (42.7%) 
Other 65 (10.9%) 5 (6.76%) 28 (13.3%) 
CP by limb distribution:
Quad/Double Hemiplegia 0 (0.00%) 12 (16.4%) 36 (17.8%) 
Hemiplegia 0 (0.00%) 6 (8.22%) 10 (4.95%) 
Diplegia 0 (0.00%) 17 (23.3%) 12 (5.94%) 
None 574 (100%) 38 (52.1%) 144 (71.3%)
ASD:
0 601 (100%) 53 (71.6%) 174 (81.3%)
1 0 (0.00%) 21 (28.4%) 40 (18.7%) 
Epilepsy:
0 601 (100%) 49 (66.2%) 173 (80.8%)
1 0 (0.00%) 25 (33.8%) 41 (19.2%) 
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SES CpG Sites and Neurodevelopment 
Multivariable logistic regression analysis of the 33 SES-associated CpG sites did 
not reveal statistically significant associations between altered methylation patterns and 
neurologic impairment (Table 3, Table 4). Odds Ratio plots were also constructed for 
each of the 66 regression models (Figure 1, Figure 2), which did not illustrate significant 
findings. To maintain a suitable scale, cg12217222 was excluded from both OR plots due 
to the values falling exceptionally outside of the range for both NCI (0.26084497) and CI 
(52.9347837). None of the P(>|z|) values calculated from these models surpassed the 95% 
confidence interval utilized for this experiment (characterized by a two-tailed z-score 
range of Z < -1.96 and Z > 1.96 with P(>|z|) < 0.05). However, three of these tests 
produced trend-level significance with outcomes surpassing the 90% confidence interval. 
CpG sites cg15519318 and cg10613063 were found to have a notable correlation 
with incidence of Non-Cognitive Impairment, as indicated by p-values of 0.052 and 
0.081, respectively. CpG site cg15519318 was pinpointed to chromosome 12, however 
the Infinium MethylationEPIC BeadChip array was unable to reveal additional 
information about cg15519318’s associated gene, genomic location, or its relation to the 
CpG island.69 cg10613063, a CpG site found on chromosome 3, is located within the 
body of the Propionyl-CoA Carboxylase Subunit β (PCCB) gene that codes for the β 
subunit of the mitochondrial enzyme of the same name.69 The final notable SES-related 
CpG, cg02765535, was found to be associated with Cognitive Impairment with a p-value 
of 0.073. This site is positioned on chromosome 12 within the body of the Netrin 4 
(NTN4) gene,69 which produces a laminin-related protein from the netrin family.  
   
 
31
With regards to the epigenetic manifestation of SES, altered methylation at 
cg15519318 is associated with the summative risk score comprised of marital status, 
insurance status, educational attainment, and food insecurity that illustrates the 
cumulative effect of socioeconomic hardships. Aberrant methylation at both cg10613063 
and cg02765535 is more specifically associated with the parent having a single 
relationship status.69  
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Table 1: Logistic Regression Estimates and Odds Ratio Probabilities for SES-
Related CpG Sites and Non-Cognitive Impairment 
 
CpG Site Estimate OR Std. Error z value Pr(>|z|)
cg09625398 -0.0114541 0.98861123 0.0201631 -0.5680734 0.56998513
cg26546864 -0.0758443 0.92696049 0.07441051 -1.0192691 0.30807524
cg03873518 -0.0061452 0.9938736 0.00619156 -0.9925184 0.32094472
cg11230111 -0.0114385 0.98862668 0.01122796 -1.0187506 0.30832137
cg12217222 -1.343829 0.26084497 4.79719883 -0.2801279 0.77937941
cg15154763 0.01749919 1.0176532 0.01239001 1.41236299 0.15784311
cg24032568 0.00804108 1.00807349 0.06335256 0.1269258 0.89899912
cg09236163 -0.0197012 0.98049158 0.04147699 -0.4749917 0.6347929
cg11173636 0.00604161 1.0060599 0.00789665 0.76508499 0.44422094
cg08707025 -0.0580185 0.94363245 0.07954021 -0.729424 0.46574234
cg21574864 -0.0009984 0.99900213 0.02606983 -0.038296 0.96945165
cg10830144 -0.0060004 0.99401759 0.01965995 -0.3052083 0.76020748
cg15519318 -0.018247 0.98191852 0.00940406 -1.9403265 0.05234002
cg01134296 -0.2613615 0.77000252 0.1724451 -1.5156215 0.12961509
cg21075783 -0.0025212 0.99748196 0.00771744 -0.3266905 0.74390198
cg14194715 0.00427985 1.00428902 0.02326301 0.18397659 0.85403182
cg15555622 0.04249417 1.04340997 0.07717056 0.55065258 0.58187186
cg07980716 -0.0154469 0.98467177 0.0198983 -0.7762936 0.43757565
cg10613063 -0.1263885 0.88127244 0.07250637 -1.7431358 0.08130989
cg22167148 -0.0200577 0.98014209 0.01588347 -1.2628049 0.20665931
cg00606069 -0.0164043 0.98372947 0.02038624 -0.8046774 0.42100585
cg24715563 -0.2353931 0.79026015 0.31340284 -0.7510879 0.45259975
cg15090198 -0.0356111 0.96501551 0.38250892 -0.0930988 0.92582511
cg00323466 -0.0021631 0.99783927 0.0093597 -0.2311042 0.81723383
cg27037498 0.19504621 1.21536715 0.36530871 0.5339216 0.59339578
cg10904858 -0.0094207 0.99062354 0.12879202 -0.0731466 0.94168948
cg05963700 -0.0196846 0.98050791 0.05965205 -0.3299897 0.74140773
cg02765535 -0.0040517 0.99595649 0.02597853 -0.1559637 0.87606166
cg05186250 -0.0883383 0.9154511 0.21639826 -0.4082211 0.68311138
cg00121303 0.01129231 1.01135631 0.02553851 0.44216807 0.65836759
cg01314054 -0.0071354 0.99288998 0.01919559 -0.3717218 0.71009999
cg01412404 -0.004384 0.99562558 0.00753147 -0.5820926 0.56050434
cg19839372 -0.0398375 0.96094557 0.02638541 -1.5098307 0.13108664
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Figure 1: Non-Cognitive Impairment Odds Ratio Plots for SES-Related CpG sites 
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Table 2: Logistic Regression Estimates and Odds Ratio Probabilities for SES-
Related CpG Sites and Cognitive Impairment 
 
CpG Site Estimate OR Std. Error z value Pr(>|z|)
cg09625398 -0.0101648 0.98988666 0.01235071 -0.8230152 0.41049932
cg26546864 0.00094546 1.00094591 0.03160877 0.02991127 0.97613782
cg03873518 -0.0053134 0.99470068 0.00398954 -1.3318374 0.18291361
cg11230111 -0.0042937 0.9957155 0.00698656 -0.6145655 0.53884169
cg12217222 3.96906066 52.9347837 3.02853813 1.31055331 0.19000872
cg15154763 -0.0045575 0.99545283 0.00478684 -0.9520974 0.34104759
cg24032568 -0.0133296 0.98675886 0.02497538 -0.5337089 0.59354293
cg09236163 0.00093665 1.00093709 0.02218648 0.04221725 0.96632551
cg11173636 0.00126858 1.00126939 0.0050488 0.25126443 0.80160967
cg08707025 -0.0450376 0.95596151 0.05272695 -0.854167 0.39301247
cg21574864 -0.0134076 0.9866819 0.01546322 -0.8670631 0.38590745
cg10830144 -0.0125791 0.98749965 0.0125388 -1.0032163 0.3157565
cg15519318 -0.0042289 0.99578006 0.00603063 -0.7012311 0.48315882
cg01134296 -0.0212822 0.97894267 0.0858582 -0.2478761 0.80423027
cg21075783 0.00031116 1.00031121 0.00507513 0.0613112 0.95111137
cg14194715 -0.014393 0.98571008 0.01438899 -1.0002789 0.31717554
cg15555622 -0.0427148 0.95818462 0.03583491 -1.1919885 0.23326577
cg07980716 -0.008001 0.99203095 0.01257384 -0.6363192 0.52456842
cg10613063 -0.0700369 0.93235942 0.0444778 -1.5746483 0.11533766
cg22167148 -0.0088997 0.99113975 0.01160252 -0.7670519 0.44305067
cg00606069 0.02635417 1.02670451 0.01728365 1.52480328 0.12730817
cg24715563 0.09034357 1.09455028 0.21014396 0.42991278 0.66725909
cg15090198 0.05902881 1.0608058 0.23309184 0.2532427 0.80008067
cg00323466 -0.0064495 0.99357129 0.00561317 -1.148989 0.25056053
cg27037498 -0.0213664 0.97886028 0.23033758 -0.0927611 0.92609336
cg10904858 -0.0541995 0.9472431 0.08017647 -0.6760028 0.4990389
cg05963700 -0.0052185 0.99479511 0.02712678 -0.1923738 0.84744942
cg02765535 -0.0312261 0.96925639 0.01742017 -1.7925262 0.07304872
cg05186250 0.23592301 1.26607683 0.15145857 1.55767356 0.11931065
cg00121303 0.0202311 1.02043714 0.01794338 1.12749655 0.2595326
cg01314054 0.01394231 1.01403996 0.01547489 0.90096306 0.36760796
cg01412404 5.41E-05 1.00E+00 0.00489181 0.01105989 0.99117566
cg19839372 -0.0061268 0.99389194 0.01524029 -0.4020129 0.68767453
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Figure 2: Cognitive Impairment Odds Ratio Plots for SES-Related CpG Sites 
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The box plots for these comparisons illustrate minimal differences in methylation 
level as percentages for all 33 CpG sites across all three categories (Figure 3). For the 
cg15519318 site, participants with no impairments had a median methylation level of 
44.1%, while those with non-cognitive impairments had a median methylation of 37.1%. 
Variance between these groups was also seen at cg10613063, where the median level of 
methylation for the NI group was 86.9% but for the NCI group was 86%. For the third 
notable difference, the median methylation of cg02765535 for the NI category was 43.1% 
while for the CI population the median methylation level was 41.6%.  
There are several CpG sites with expansive interquartile ranges across all 
impairment categories, such as cg00323466 and cg01412404, but there are also numerous 
sites with limited ranges not visible on the graph, including cg12217222 and 
cg27037498. Locations with minimal variation between participants are at the extremes 
of methylation, as characterized by the 0.2% median methylation across categories at 
cg12217222 and 97.5% median methylation across categories at cg27037498. 
Conversely, variation both within groups and between groups increases as methylation 
levels fall farther away from the extremes, as seen in the interquartile ranges of 
approximately 35%, 40%, and 25% for the NI, NCI, and CI groups at cg01412404.  
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Figure 3: Box Plots of Methylation Levels for each SES-Related CpG Site in NI (1), NCI (2), 
and CI (3) 
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EWAS: Associating CpG Methylation and Neurodevelopmental Outcome 
Although the logistic regression analysis of the SES-related CpG sites produced 
statistically insignificant results, a secondary EWAS found several associations between 
altered CpG methylation and poor neurodevelopmental outcome. Non-Cognitive 
Impairment was found to be significantly correlated with four aberrant CpG sites: 
cg07322235 (log2FC=-0.55, q=3.33E-03), cg13592565 (log2FC=-1.17, q=3.53E-02), 
cg13723879 (log2FC =0.93, q=3.53E-02), and cg24387818 (log2FC=0.71, q=4.17E-02) 
(Table 5). Cognitive Impairment was also found to be associated with four abnormally 
methylated CpG sites: cg23081580 (log2FC=-0.36, q=4.01E-02), cg14134658 
(log2FC=0.26, q=7.83E-02), cg00762003 (log2FC=-1.05, q=7.83E-02), and cg08546514 
(log2FC=0.40, q=7.83E-02) (Table 5). As indicated by negative log2FC values, four of 
the eight significant sites were hypomethylated in comparison to the accepted 
methylation level, while the other four remaining sites exhibited hypermethylation. This 
equal stratification of increased and decreased methylation levels was also seen within 
groups, with both CI and NCI categories having two hypomethylated CpG sites and two 
hypermethylated CpG sites. 
With regards to the location of these CpG sites, six of the eight significantly 
altered methylation patterns were positioned within known protein-coding genes (Table 
5). Of the four CpG sites associated with Non-Cognitive Impairment, cg13723879 was 
found within the Neuregulin-3 (NRG3) gene and cg24387818 was discovered within the 
Premature Ovarian Failure Actin Binding Protein 1B (POF1B) gene. All four altered 
methylation patterns significantly correlated with Cognitive Impairment were situated 
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within the coding region of known genes: cg23081580 was found within the Six-
Transmembrane Epithelial Antigen of Prostate 2 Metalloreductase (STEAP2) gene, 
cg14134658 was located in the Ly1 Antibody Reactive (LYAR) gene, cg00762003 was 
detected in the 1-Acylglycerol-3-Phosphate O-Acyltransferase 3 (AGPAT3) gene, and 
cg08546514 was observed within the Ninein-like protein (NINL) gene. 
 
Table 3: EWAS CpG Sites Significantly Correlated with NCI and CI 
 
 
KEY (Tables 5 and 6): log2FC= log2 fold change (FC) of average M values between two 
levels of a given phenotype; AveExpr= average rate of gene expression; t= moderated t-
statistic for test of association; Adj. P Value= adjusted p value for FDR<0.1; B= log-odds 
that the CpG site is differentially methylated; SE= Standard Error.  




cg07322235 -0.5531412 4.92291803 -6.025147 3.85E-09 0.00332926 3.33142572 0.09180543
cg13592565 -1.172266 4.92872096 -5.4108503 1.09E-07 0.03529501 2.48665419 0.21665097
cg13723879 0.93007798 -5.1916186 5.3876075 1.23E-07 0.03529501 2.44852911 0.17263284
NRG3; NRG3; 
NRG3
cg24387818 0.70643436 -4.1984521 5.29951487 1.93E-07 0.0416581 2.26716037 0.1333017 POF1B
Cognitive CpG sites:
cg23081580 -0.3609776 -6.1329647 -5.5725535 4.64E-08 0.04006052 6.92101831 0.06477777
STEAP2; 
STEAP2; STEAP2
cg14134658 0.25847994 2.1669353 5.23815371 2.64E-07 0.07826763 5.57945301 0.04934562 LYAR; LYAR
cg00762003 -1.0485589 1.94139886 -5.1866412 3.42E-07 0.07826763 5.14148867 0.20216531
AGPAT3; 
AGPAT3
cg08546514 0.40284331 -0.1579744 5.17503489 3.62E-07 0.07826763 5.27514757 0.07784359 NINL




 The purpose of this study was to evaluate the relationship between exposure to 
socioeconomic adversity during gestation and the development of neurological disorders 
through epigenetic modification of DNA methylation levels. Given the previously well-
defined impact of socioeconomic status on neurologic outcome45,46,49–64 as well as 
epigenetic alterations,69–74 we hypothesized that the manifestation of societal hardships in 
epigenetic changes would also correlate with the incidence of Neurodevelopmental 
Disorders (NDDs). Our primary findings revealed marginal associations of the SES-
related CpG sites cg15519318 and cg10613063 with Non-Cognitive Impairment, as well 
as cg02765535 with Cognitive Impairment, however no significant correlations between 
these two categories of variables. Our secondary findings from evaluating the relationship 
between altered methylation status and neurodevelopment uncovered 4 CpG sites 
associated with Non-Cognitive Impairment and 4 CpG sites associated with Cognitive 
Impairment. While these findings shed light on the interplay of epigenetics and 
neurological phenotypic expression, this study was unable to prove, or disprove, our 
original hypothesis. 
 
Demographics and Neurodevelopmental Disorder Prevalence 
An increase in both categories of NDD incidence in neonates born at 23-24 weeks 
gestation as well as those with below-average birthweight is consistent with previous 
findings that gestational age is inversely correlated with risk for neurodevelopmental 
impairment.42–44,69,71 The unequal sex-stratification seen in the CI group (male N=127, 
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female N=87) is consistent with previous findings that rates of intellectual disability are 
significantly higher among males.63 This trend has been identified in many other NDDs 
including ASD63 and CP,98 while sex differences within epilepsy are more evenly split 
between subtypes.99 Given the greater number of participants with ASD or CP diagnoses 
in comparison to those with epilepsy, the equal distribution of the NCI group between 
females (N=37) and males (N=37) is an interesting deviation from the expected 
stratification towards males. Due to our exclusion of probes for CpGs on sex 
chromosomes from our analysis, we are unable to determine whether these findings were 
a result of methylation alterations in genes located on the sex chromosomes. 
The notably higher level of white children diagnosed with Non-Cognitive 
Impairments (ASD, CP, and epilepsy) in comparison to Black and “Other” children in 
this study was an intriguing and unexpected outcome. Our findings mirror the racial 
differences extensively documented in the US population for Autism Spectrum Disorder 
prevalence, which has been majorly attributed to the under-ascertainment of cases due to 
insufficient access to healthcare and diagnostic evaluation.63 Given the strict adherence of 
our providers and researchers to implementing protocol uniformly for each participant, 
this bias should not exist among the participants included in this study. However, a 
possible explanation of these racial differences in NCI prevalence could be that expecting 
mothers with low SES, which is a population disproportionately comprised of non-white 
communities,49 had greater difficulty accessing healthcare at one of the study’s fourteen 
institutions due to other financial constraints, such as transportation access and costs,54 
thus preventing them from having the opportunity to partake in this study. In light of the 
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majority of participants being white (63%) and experiencing zero of the four measures of 
socioeconomic adversity (62%), future projects should strive to make participation in 
these studies more accessible for a spectrum of populations in order to increase the 
statistical power of these societal influences that predominantly impact low SES 
populations as well as the external validity of their findings. 
Interestingly, ASD was the least prevalent NDD within our cohort (N=61, 
7.12%), while Cerebral Palsy, a disorder with an established trend of higher prevalence in 
Black populations,49 was the most prevalent Non-Cognitive Impairment (N=93, 11.0%). 
The absence of this trend in our cohort could coincide with recent developments in CP 
incidence beyond the scope of perinatal complications. Classically, the development of 
Cerebral Palsy has been largely attributed to complications during delivery (hypoxic-
ischemia, stroke, bradycardia, etc.)35; due to the inadequate access to quality healthcare 
for Black populations, this has resulted in a higher incidence of this disease within the 
Black community.49 The improvement of delivery practices, such as fetal heart 
monitoring and cesarean section procedures, in the last several decades without 
significant decrease in CP prevalence has revealed that these perinatal events in the 
setting of CP are a by-product of previously established abnormalities and genetic 
predispositions, rather than a causal factor of the disease.35 Given that all of the 
participants within this cohort were delivered in one of fourteen medical centers and 
therefore exposed to the same conditions, the quality of care between patients in each 
medical center should be of the same level. Further research of this cohort could be done 
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to determine whether the quality of care offered at each institution impacted CP 
prevalence. 
 
SES-Associated CpG Methylation & Neurodevelopmental Disorders  
Contrary to our initial hypothesis that the biological manifestation of 
environmental stress displayed in 33 CpG sites previously associated with SES would 
also be associated with neurodevelopment, our findings did not indicate a significant 
correlation between altered methylation patterns at these sites and worsened neurologic 
outcome. We chose to explore this topic because finding a correlation between these 
particular methylation sites and neurodevelopment could have served as a social 
predictive measure for neurologic deficit. This, in turn, could have contributed evidence 
to support legislation that improves the quality of and accessibility to various public 
resources concerning health and overall quality of life. While the four socioeconomic 
factors evaluated in this study represent considerable sources of adversity, there are a 
substantial amount of other societal factors that contribute to adverse health outcomes 
that should be explored in the future. This includes disparate educational opportunities,100 
healthcare quality and access,101 housing conditions,102 employment exclusions,102 
transportation limitations,103 and many others. Given our lack of significant findings, it is 
possible that the CpG alterations related to the four SES indicators evaluated in this study 
have a weaker correlation with neurologic outcome than the epigenetic changes 
associated with other forms of social adversity. Thus, these four measures may not play 
   
 
44
as important of a role in neurodevelopment in comparison to other types of societal 
stress. 
Although the first portion of this experiment did not culminate in significant 
results, several interesting trends emerged from its analysis. Two of the three SES-related 
CpG sites having the strongest trends with neurologic outcome are located within genes 
that have considerable impact on neurodevelopment. Propionyl-CoA Carboxylase 
Subunit β, the protein coding gene that includes CpG site cg10613063 associated with 
Non-Cognitive Impairment, is a mitochondrial enzyme highly expressed in the fetal brain 
during the embryonic stage. Although not directly involved in neurological processes 
beyond early gestation, inadequate function of this enzyme in the adrenal gland, liver, 
and kidney can result in movement disorders, intellectual disability, and epilepsy 
secondary to metabolic disorders such as Propionic Acidemia.104 Similarly, the protein 
coding gene Netrin 4 contains the CpG site cg02765535, which was found to be 
marginally associated with Cognitive Impairment. This protein contributes to axon 
guidance, neurite growth and migration, and neuron remodeling,105 and its malfunction 
has been linked to several neurodevelopmental disorders including Tourette Syndrome.106 
With regards to the association of these three CpG sites with summative SES risk 
score (cg15519318) and single marital status (cg10613063 and cg02765535), this also 
reflects the original study’s finding69 that these two forms of adversity had the greatest 
number of associations with altered DNA methylation (summative score=14 sites, 
single=15 sites) in comparison to the other SES indicators (food insecurity=2 sites, high 
school diploma or less=1 site, and public health insurance=1 site). These outcomes 
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further highlight that every component of our external environment and societal 
experience does not have the same biological impact, particularly when they accumulate 
and interact with one another.73 Breaking down the umbrella term of socioeconomic 
status into its multiple components allows us to determine the more prominent promoters 
of adverse health outcomes, such as parental marital status. By taking a finer lens to 
environmental and social factors, we hope to promote the development and 
implementation of health risk evaluations that not only incorporate but place weight on 
the role of societal factors in development and exacerbation of disease. 
Another interesting trend can be seen in the pattern of variance among the SES-
CpG box plots (Table 3). As previously noted, the CpG sites with methylation levels 
occurring close to either 0% or 100% were most uniform among all participants and 
variation increased as methylation levels travelled away from these extremes. The lack of 
variation at CpG sites such as cg12217222, which has a median of only 0.2% methylation 
with no visible range across all subjects and is thus unencumbered by methylation to 
proceed with transcription, could indicate that the proteins they code for benefit from 
adapting to the experience of socioeconomic adversity but play an essential role common 
to every human being regardless of neurodevelopmental status. Ironically, the gene 
containing cg12217222 codes for Down-Regulator of Transcription 1 (DR1), a TATA 
Box Binding Protein-associated phosphoprotein that controls the rate of RNA polymerase 
II transcription by inhibiting the assembly of the preinitiation complex.107 This further 
supports the concept that adaptive genetic expression is a crucial and active component of 
daily life. 
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In similar theory, the sites with greater variation may play a role expressing genes 
involved in neurodevelopment. Potassium Voltage-Gated Channel Interacting Protein 4 
(KCNIP4), the gene that contains the variably methylated cg00323466, encodes a protein 
that inhibits neuronal excitability via A-type currents in response to intracellular 
calcium.108 Given the involvement of this protein in such a vital neurological process and 
the extensive implication of dysregulated neuronal excitability in epilepsy,109 ASD,110 
and ID,111 this spectrum of phenotypic expression across participants could lend itself to 
the intricacies of each NDD’s pathogenesis as well as which degrees of physiological 
deviation correlate with each disorder. Given the lack of literature concerning this 
pattern, further research should be conducted regarding its validity and whether it could 
serve as a predictive marker of susceptibility to alteration. 
 
EWAS CpG Methylation & Neurodevelopmental Disorders 
Although our primary analysis of the epigenetic connection between 
socioeconomic adversity and neurodevelopment proved to be insignificant, evaluation of 
CpG alterations throughout the epigenome in the presence of neurodevelopmental 
impairment was very informative. The differentially methylated protein-coding genes 
uncovered in this study have a spectrum of influences on health outcomes. Several of 
these genes play integral roles in the development and function of the central nervous 
system. For example, NRG3, the gene that contains NCI-associated CpG site 
cg13723879, encodes the ligand for epidermal growth factor tyrosine kinase ERBB4 that 
activates intracellular signaling cascades for neuroblast proliferation, migration, and 
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differentiation.112 Prior studies have linked diminished production and function of this 
protein to several neurological disorders, including Alzheimer’s disease, ASD, and 
cognitive deficit in the setting of schizophrenia.113 1-Acylglycerol-3-Phosphate O-
Acyltransferase 3 (AGPAT3), the gene containing the CI-associated CpG site 
cg00762003, produces an enzyme of the same that converts lysophosphatidic acid into 
phosphatidic acid within the phospholipid biosynthetic pathway and contributes to 
retrograde transport from the Golgi complex.114 The AGPAT3 enzyme also acts on 
lysophosphatidylcholine, the major source of docosahexaenoic acid (DHA) that is critical 
in neurodevelopment.115 Upregulation of this enzyme could cause a “nutritional toxicity” 
of excessive DHA accumulation in the brain that results in competitive displacement of 
other fatty acids, such as arachidonic acid and omega-6 fatty acids, that play vital roles in 
myelination, plasticity, and neuronal signaling.116,117 Ninein-like protein, which is 
produced by the NINL gene containing CI-associated CpG site cg08546514, is involved 
in the microtubule organization of interphase cells and cilia for organelle development 
and cell growth.118 Decreased expression of this gene has been implicated in the 
development of Joubert Syndrome, a complex neurodevelopmental disorder resulting 
from cerebellar malformation that is characterized by hypotonia and ataxia, delayed 
acquisition of motor and language skills, and intellectual disability.119 Additional adverse 
neurologic outcomes include Autism Spectrum Disorder and forms of progressive vision 
and hearing loss, such as Usher Syndrome, Fundus Dystrophy, and Inherited Retinal 
Disorder.118 
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Other identified genes were not directly involved in neurodevelopment; however, 
their malfunction could lead to detrimental effects on the nervous system. The Six-
Transmembrane Epithelial Antigen of Prostate 2 Metalloreductase (STEAP2) gene that 
contains the CI-associated CpG site cg23081580 produces an enzyme of the same name 
that functions as an integral membrane protein responsible for stimulating cellular uptake 
of iron and copper.120 Diminished function of this transporter can cause 
aceruloplasminemia, a severe neurodegenerative disorder resulting from the 
accumulation of iron in the brain that can cause cognitive decline as well as various 
movement disorders including cerebellar ataxia, chorea, and dystonia.121 The gene 
product of Premature Ovarian Failure Actin Binding Protein 1B (POF1B), which 
includes the NCI-associated CpG site cg24387818, plays a critical role in tissue 
organization and cytoskeleton regulation through binding actin filaments for cell 
adhesion. Loss of protein function due to translocation in the critical region of the X 
chromosome long arm can result in several abnormalities, including X-linked intellectual 
disability and deafness.122 
One gene of particular interest has no obvious connection with the central nervous 
system. Ly1 Antibody Reactive (LYAR), which carries the CI-associated CpG site 
cg14134658, encodes for a cell growth-regulating nucleolar protein involved in rRNA 
production maintenance, transcriptional regulation, and promotion of cell proliferation in 
undifferentiated cells. This protein also negatively regulates the innate immune response 
by impairing the DNA-binding activity of transcription factor Interferon Regulatory 
Factor 3 and inhibiting Nuclear Factor kappa B-mediated expression of proinflammatory 
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cytokines. The upregulation of this protein has been implicated in pathologies outside of 
the scope of extrauterine neurodevelopment, including the lethal neural tube defect 
exencephaly, in which the fetal brain develops outside of the skull, and neuroblastoma 
tumorigenesis.123,124 However, given LYAR’s roll in suppressing the immune response in 
order to preserve the host, upregulation of this gene could be a byproduct of placental or 
uterine infection during gestation. As previously mentioned, systemic inflammation in 
response to infection within the underdeveloped brain can induce chemokine production 
and recruit immune cells through the primitive blood brain barrier and into the 
parenchyma, resulting in white matter damage.41 
The differentially methylated sites correlated with adverse neurodevelopment 
were uniformly stratified based on the type of neurodevelopmental impairment, however 
when the structure of these categories is taken into consideration, the same number of 
changes in methylation pattern attributed to one diagnosis (cognitive impairment) is 
associated with a group of several diagnoses (cerebral palsy, autism spectrum disorder, 
and epilepsy). This outcome reflects the greater prevalence of cognitive impairment, with 
214 participants being diagnosed by an LPA of 3 or 4, in comparison to CP, ASD, and 
epilepsy, whose pooled population was 220 participants (Table 2). However, despite the 
possibility of similar origins and notable risk for comorbidity amongst them,125 these are 
three vastly different diseases with varying pathologies and presentations. Although the 
four NCI sites are likely not associated with all three disorders, there is no way to assume 
the distribution of these associations based on this model. Additionally, while the NCI 
category strictly includes participants with CP, ASD, and/or epilepsy diagnoses, the CI 
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category includes all participants with cognitive impairment regardless of comorbidity 
with other NDDs. This is of particular interest when CpG sites such as cg23081580 and 
cg08546514, which are associated with the CI category, are components of genes 
implicated in the development of CP and ASD. Further stratifying this variable to analyze 
the correlation of these CpG sites with each diagnosis could provide greater insight into 
the similarities and nuances of each disease’s pathogenesis with the hope of elucidating 
epigenetic risk level of comorbidity as well as specific targets for therapy. 
 
Limitations 
Several factors should be taken into account while interpreting the results of this 
study. We did not utilize the methylation status of participants at 10 years old in our 
analysis, but rather solely evaluated the presence of an NDD diagnosis in correlation with 
placental DNA methylation. Future study including CpG methylation at 10 years old 
could possibly reveal stronger associations with directionality. Additionally, the analysis 
of methylation status was restricted to placental DNA. Although it is well established that 
the placenta acts as a bridge connecting the fetus to its environment and thus embodies 
the physiological manifestation of fetal experience and exposure,24–28 it is also known 
that certain types of methylation occur in tissue specific patterns.126 Our approach to this 
study was to evaluate placental DNA methylation patterns as a “snapshot” of the 
signaling pathways occurring during fetal development in order to determine if this 
“snapshot” could serve as a predictive measure for neurologic outcome. As such, we do 
not make the assumption that these CpG alterations would be found in the brain of the 
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child during gestation or at 10 years old. In light of these restrictions, future studies 
should investigate DNA methylation in a cell type from the nervous system that could be 
evaluated at birth and throughout life to provide a consistent measure with greater tissue 
specificity. 
With regards to the participant pool, conducting research with the multicenter 
ELGAN cohort helped increase magnitude and diversity of patient population; however, 
given the stratification of each category with numerous variables, the group sizes 
considerably downsize during analysis. This is notable with types of neurological 
impairment (24.5% LPA 3 or 4, 11.0% CP, 7.81% epilepsy, 7.12% ASD) as well as in 
types of socioeconomic adversity (21.7% single parent, 14.6% low parental EA, 35.1% 
public insurance, and 22.6% food insecurity), particularly when calculating the 
summative score. As previously discussed, expanding future cohorts by recruiting 
additional medical centers could increase the power behind potential findings. 
Additionally, despite the strict protocol that was developed and implemented for all 
forms of participant evaluation and data collection, the vastness of this program increases 
heterogeneity of study samples due to the possibility of slightly different approaches to 
the diagnostic methods by each provider/researcher.  
 
Future Directions 
Although the 33 SES-associated CpG sites in question were not significantly 
correlated with an increased risk for adverse neurologic outcomes, a considerable amount 
of previous research has illuminated this relationship between societal factors and 
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neurodevelopment.45,46,49–64 Given that this well-established association exists, this 
avenue could be further explored by evaluating the correlation of the CpG sites identified 
by EWAS in this study, as well as other sites previously associated with 
neurodevelopmental impairment,70,75–78 with socioeconomic adversity. As previously 
mentioned, in order to gain a more specific understanding of neurodevelopmental 
impairment, future models could account for specifics NDD diagnoses individually, 
severity, and comorbidities. Additionally, exploring the interactive effects of CpG 
methylation and socioeconomic adversity on NDDs as well as possible confounding 
variables could elucidate a stronger relationship between societal stress and adverse 
neurodevelopment. 
A future direction we plan to explore is the possible modifying effect of changes 
in SES on neurologic outcomes by calculating the change in each participant’s 
summative risk score of socioeconomic adversity between birth and 10 years old. By 
categorizing participants into those who experienced an increase, no change, or decrease 
in adversity, we hope to evaluate the impact of SES indicators on NDD prevalence 
beyond gestation.  
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